GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ARQT · Sep 30, 2024

Arcutis Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001787306-24-000153General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

457.17% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.32% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-77.51% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

31.31% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

87.70% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-87.29% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

43.57% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

22.88% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building

Mar 31, 20240/8 normalizedLevel 3 Jun 30, 20240/9 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/9 normalizedLevel 3 Sep 30, 20250/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20268/9 normalizedLevel 3 Jun 30, 20268/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 660.47%
Current: 457.17%
Delta: -203.30%

Capex Intensity Increased

Previous: 0.00%
Current: 0.32%
Delta: 0.32%

Cash Generation Increased

Previous: -146.21%
Current: -77.51%
Delta: 68.71%

Inventory Pressure Decreased

Previous: 44.98%
Current: 31.31%
Delta: -13.67%

Margin Decreased

Previous: 88.77%
Current: 87.70%
Delta: -1.07%

Profitability Increased

Previous: -162.28%
Current: -87.29%
Delta: 74.99%

R And D Intensity Decreased

Previous: 62.54%
Current: 43.57%
Delta: -18.97%

Sbc Intensity Decreased

Previous: 40.58%
Current: 22.88%
Delta: -17.70%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ARQT Fundamental State →Has State · Arcutis Biotherapeutics, Inc. →Transitioned To · ARQT Fundamental State →Transitioned To · ARQT BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ARQT CAPEX_INTENSITY_INCREASED →Transitioned To · ARQT CASH_GENERATION_INCREASED →Transitioned To · ARQT INVENTORY_PRESSURE_DECREASED →Transitioned To · ARQT MARGIN_DECREASED →Transitioned To · ARQT PROFITABILITY_INCREASED →Transitioned To · ARQT R_AND_D_INTENSITY_DECREASED →Transitioned To · ARQT SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.